Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by davikingon Jun 03, 2016 10:30am
147 Views
Post# 24931109

RE:RE:Cormack analyst

RE:RE:Cormack analyst

SWYG, Oh, I'm sure you will give us your take on what has been said. You are so enlightened, you think you are JC. The exact words were: "Maintaining Buy (S) Recommendation, $1.50 Target We reiterate the speculative, high risk nature of this investment, considering the conflicting evidence regarding Toraymyxin efficacy in the scientific domain, in addition to the mortality assumptions made post protocol amendment." I can't provide a link but if you ask IR for a copy I'm sure they will pass it along. GO FOR IT SWYG. You've been whinging that there has been no coverage and now there is, you're whinging again. You are never happy with the way things are. You think I'm bashing. FU! I just provide information and ask questions to get information. You overburden us with your diatribe/BS/schizoid view!! We wait with baited!! breath for your in depth analysis.
Bullboard Posts